演題抄録

臓器別シンポジウム

開催概要
開催回
第58回・2020年・京都
 

肺癌のゲノム医療

演題番号 : SY1-4

[筆頭演者]
豊岡 伸一:1 
[共同演者]
久保 寿夫:2

1:岡山大学・呼吸器・乳腺内分泌外科、2:岡山大学病院・アレルギー・呼吸器内科

 

Since the discovery of EGFR gene alteration as a driver mutation in 2004, therapeutic strategy based on genome information of cancer has been established in lung cancer, especially adenocarcinoma of the lung. At present, driver mutations with molecular targeting drugs are identified in approximately 50% of lung adenocarcinoma, which can be detected by cancer panel test with next generation sequencer. The alteration of six genes (EGFR, ALK, ROS1, BRAF, NTRK, MET) can be treated with their inhibitors. In addition, other driver alterations such as RET and KRAS show their potentials as new therapies. In this presentation, we will show the current status of genomic medicine for lung cancer.

前へ戻る